Prof. Torsten Hanke

Aortic Highlights, 2024

Dr. Maximilian Emmert

Aortic Highlights course, 2024

Francesco Onorati

Tom Nguyen

Prof. Kalavrouziotis

Edwards Lifesciences at EACTS 2022: State of the art in the treatment of aortic valve regurgitation in young patients

Prof. Augusto D’Onofrio

MVT Aortic 2022, vol.1

– Not only about hemodynamics, this lecture provides comparisons among three bioprostheses

– Similar clinical outcomes, better hemodynamic results, and shorter ICU stays for rapid deployment valves… but newer bioprosthesis tissue technology may raise the bar even higher

Prof. Marjan Jahangiri

MVT Aortic 2022, vol.1

– Pay attention to comorbidities, the anticoagulation choice may not as simple as it seems

– Be aware of the limitations of the currently available studies, question them in a logical manner

Prof. Bart Meuris

MVT Aortic 2022, vol.1

• Shorter hospital stays, less anticoagulation, long-term financial savings? Hear about the data of an expert’s personal experience.

• With advanced anti-calcification treatment, the future of bioprostheses is promising not only for patient outcomes, but even from a financial perspective

Prof. Kocher – EACTS 2021

Dr. Bart Meuris, Belgium

Keywords: aortic bioprostheses; aortic valve replacement; structural valve degeneration

Long-term durability is a key concern for bioprosthetic valves, but measuring structural valve degeneration (SVD) has been complicated by different SVD definitions. The RESILIENCE trial is the first prospective study to use both clinical and imaging SVD definitions to assess long-term valve durability.

This summary describes the design of this multicentre, prospective trial. The trial will investigate predictors of durability and time to failure in RESILIA tissue valves, which are treated to minimise free aldehydes and preserve the tissue.

The trial will include up to 250 adults from up to 15 centres. The primary endpoint is time to valve failure due to SVD, while the secondary endpoints are valve leaflet calcification volume and SVD stage 2 or 3. Non‑contrast computed tomography and transthoracic echocardiography will be carried out at 5, 7, 9 and 11 years after valve implantation to assess valve morphology and haemodynamics.

Download below to keep up to date with the latest research in aortic valve replacement.

Click here to access the full publication

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meet the requirements for bearing the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, PERI, PERIMOUNT, and RESILIA are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks or service marks are the property of their respective owners.

EACTS Annual Meeting – Lisboa, October 2019

Virtual Symposium